National Conference to Address Neuroplastic Symptoms Affecting Nearly Half of US Adults

The Association for the Treatment of Neuroplastic Symptoms will convene its national conference from September 28-30 in Boulder, Colorado, bringing together medical professionals, researchers, and mental health experts to address the growing prevalence of neuroplastic symptoms affecting millions of Americans. The conference comes at a critical time as new research reveals the staggering scope of this public health issue.

A groundbreaking national survey to be presented at the conference indicates that nearly half of US adults experience pain or illness that is either unexplained or not responding to conventional treatment. According to Dr. David Clarke, president of the ATNS, this represents the first comprehensive survey of its kind and addresses critical questions affecting 40% of people who seek medical care for symptoms. The research suggests that a large majority of these cases likely involve neuroplastic symptoms rather than structural damage or disease.

Neuroplastic symptoms result from stress-induced changes in nerve pathways within the brain rather than from injury or illness. These conditions include fibromyalgia, migraines, irritable bowel syndrome, chronic back pain, many long COVID cases, and dozens of other disorders. The conference will feature more than 40 leading experts who will explore the latest advances in diagnosing and treating these brain-generated conditions.

The ATNS promotes an evidence-based, biopsychosocial approach called Neuroplastic Recovery Therapy that focuses on uncovering stress, trauma, and unrecognized emotions that contribute to symptom patterns. This method enables patients to gain control over their symptoms without relying on drugs, surgery, or expensive treatments. As Dr. Clarke emphasizes, Neuroplastic Recovery Therapy is the only treatment backed by gold standard science from randomized trials published in top medical journals, including the American Medical Association Psychiatry journal.

The implications of this conference extend beyond the medical community to the nearly 50% of American adults who may be suffering from neuroplastic symptoms. The research and treatments discussed could revolutionize how chronic pain and unexplained illnesses are addressed, offering safer, more affordable, and more effective alternatives to traditional medical approaches. The conference represents a significant step toward ending what the organization describes as a chronic pain epidemic through increased awareness, improved diagnosis, and evidence-based treatment methodologies.

For those interested in learning more about neuroplastic symptoms and evidence-based treatments, additional information is available at https://symptomatic.me. The organization's commitment to addressing this widespread health issue through scientific research and innovative treatment approaches positions this conference as a pivotal event in the evolving understanding and management of chronic pain conditions.